Jan J G M Verschuuren

List of Publications by Year
in descending order

177 papers	15,293 citations	25034 57 h-index	19749 117 g-index
183 all docs	183 docs citations	183 times ranked	9664 citing authors

#	Article	IF	Citations
1	Testâ€“Retest Reliability of Repetitive Ocular Vestibular Evoked Myogenic Potentials in Myasthenia Gravis Patients and Healthy Control Subjects. Journal of Clinical Neurophysiology, 2024, 41, 265-270.	1.7	0
2	DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study. Journal of Crohn's and Colitis, 2022, 16, i079-i079.	1.3	2
3	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	10.2	41
4	Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 2022, 20, 100.	5.5	15
5	Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatology, The, 2022, 4, e338-e350.	3.9	88
6	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	3.9	33
7	The neurocognitive profile of adults with Becker muscular dystrophy in the Netherlands. Journal of Neuromuscular Diseases, 2022, , 1-11.	2.6	1
8	The Black Box of Technological Outcome Measures: An Example in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 555-569.	2.6	3
9	International Consensus Guidance for Management of Myasthenia Gravis. Neurology, 2021, 96, 114-122.	1.1	272
10	Seizure-related 6 homolog like 2 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	36
11	The feasibility of quantitative MRI of extraâ€ocular muscles in myasthenia gravis and Graves' orbitopathy. NMR in Biomedicine, 2021, 34, e4407.	2.8	23
12	Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay. Scientific Reports, 2021, 11, 5952.	3.3	13
13	Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
14	Preserved thenar muscles in nonâ€ambulant Duchenne muscular dystrophy patients. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 694-703.	7.3	5
15	Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy. Neurology, 2021, 97, e513-e522.	1.1	17
16	Compliance to DMD Care Considerations in the Netherlands. Journal of Neuromuscular Diseases, 2021, 8, 927-938.	2.6	2
17	Prevalence and associated factors of fatigue in autoimmune myasthenia gravis. Neuromuscular Disorders, 2021, 31, 612-621.	0.6	14
18	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	10.2	194

#	Article	IF	Citations
19	Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neuromuscular Disorders, 2021, 31, 622-632.	0.6	10
20	Clinical Management of Duchenne Muscular Dystrophy in the Netherlands: Barriers to and Proposals for the Implementation of the International Clinical Practice Guidelines. Journal of Neuromuscular Diseases, 2021, 8, 503-512.	2.6	3
21	Association of Elbow Flexor MRI Fat Fraction With Loss of Hand-to-Mouth Movement in Patients With Duchenne Muscular Dystrophy. Neurology, 2021, 97, e1737-e1742.	1.1	12
22	Occurrence of symptoms in different stages of <scp>Duchenne</scp> muscular dystrophy and their impact on social participation. Muscle and Nerve, 2021, 64, 701-709.	2.2	9
23	Myasthenia gravis: do not forget the patient perspective. Neuromuscular Disorders, 2021, 31, 1287-1295.	0.6	9
24	Longâ€term followâ€up, quality of life, and survival of patients with Lambertâ€Eaton myasthenic syndrome. Neurology, 2020, 94, e511-e520.	1.1	24
25	Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Scientific Reports, 2020, 10, 10546.	3.3	8
26	Novel free-circulating and extracellular vesicle-derived miRNAs dysregulated in Duchenne muscular dystrophy. Epigenomics, 2020, 12, 1899-1915.	2.1	4
27	Multiâ€parametric MR in Becker muscular dystrophy patients. NMR in Biomedicine, 2020, 33, e4385.	2.8	14
28	Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis. Neurology, 2020, 94, e1693-e1701.	1.1	7
29	Treating muscle-specific kinase myasthenia gravis from the inside out. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	2
30	Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscular Disorders, 2020, 30, 631-639.	0.6	43
31	Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambertâ€Eaton myasthenic syndrome. Muscle and Nerve, 2020, 62, 111-114.	2.2	6
32	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. Journal of Neuromuscular Diseases, 2020, 7, 297-300.	2.6	8
33	Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature. Journal of Neuromuscular Diseases, 2019, 6, 369-376.	2.6	12
34	Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscular Disorders, 2019, 29, 664-670.	0.6	17
35	A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine, 2019, 37, 919-925.	3.8	25
36	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.1	169

#	Article	IF	Citations
37	The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain, 2019, 142, 1631-1643.	7.6	73
38	Myasthenia gravis. Nature Reviews Disease Primers, 2019, 5, 30.	30.5	421
39	Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study. Neuromuscular Disorders, 2019, 29, 261-268.	0.6	36
40	Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Experimental Neurology, 2019, 317, 133-143.	4.1	25
41	MuSK myasthenia gravis monoclonal antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e547.	6.0	64
42	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. Journal of Neuroimmunology, 2019, 326, 14-18.	2.3	12
43	Sensitivity of MGâ€ADL for generalized weakness in myasthenia gravis. European Journal of Neurology, 2019, 26, 947-950.	3.3	10
44	IgG4â€mediated autoimmune diseases: a niche of antibodyâ€mediated disorders. Annals of the New York Academy of Sciences, 2018, 1413, 92-103.	3.8	54
45	Distinct representation of muscle weakness in QMG and MG-ADL. Lancet Neurology, The, 2018, 17, 204-205.	10.2	10
46	Passive transfer models of myasthenia gravis with muscleâ€specific kinase antibodies. Annals of the New York Academy of Sciences, 2018, 1413, 111-118.	3.8	4
47	Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients. Epigenomics, 2018, 10, 875-889.	2.1	23
48	Improved olefinic fat suppression in skeletal muscle <scp>DTI</scp> using a magnitudeâ€based dixon method. Magnetic Resonance in Medicine, 2018, 79, 152-159.	3.0	27
49	Translation and validation of the 15â€item Myasthenia Gravis Quality of life scale in Dutch. Muscle and Nerve, 2018, 57, 206-211.	2.2	4
50	Neuromuscular synapse electrophysiology in myasthenia gravis animal models. Annals of the New York Academy of Sciences, 2018, 1412, 146-153.	3.8	10
51	Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis. Journal of Neuromuscular Diseases, 2018, 5, 261-264.	2.6	8
52	Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. Neuromuscular Disorders, 2017, 27, 458-464.	0.6	53
53	Proton Magnetic Resonance Spectroscopy Indicates Preserved Cerebral Biochemical Composition in Duchenne Muscular Dystrophy Patients. Journal of Neuromuscular Diseases, 2017, 4, 53-58.	2.6	4
54	Neuromuscular diseases: hope and hurdles in clinical trials. Lancet Neurology, The, 2017, 16, 12-13.	10.2	0

#	Article	IF	Citations
55	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. Journal of Autoimmunity, 2017, 77, 104-115.	6.5	92
56	Elevated phosphodiester and T₂ levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients. NMR in Biomedicine, 2017, 30, e3667.	2.8	45
57	A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine, 2017, 35, 6290-6296.	3.8	13
58	Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Scientific Reports, 2017, 7, 12575.	3.3	123
59	Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes. Annals of Clinical and Translational Neurology, 2017, 4, 680-686.	3.7	38
60	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 327-335.	2.6	8
61	Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database. Journal of Neuromuscular Diseases, 2017, 4, 293-306.	2.6	125
62	Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis. Orphanet Journal of Rare Diseases, 2017, 12, 88.	2.7	8
63	Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe. Muscle and Nerve, 2017, 55, 819-827.	2.2	12
64	Ephedrine treatment for autoimmune myasthenia gravis. Neuromuscular Disorders, 2017, 27, 259-265.	0.6	26
65	Activity limitations in myasthenia gravis and relation to clinical variables. Muscle and Nerve, 2017, 56, 64-70.	2.2	1
66	Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. Scientific Reports, 2017, 7, 17888.	3.3	20
67	Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24â€“month follow-up. PLoS ONE, 2017, 12, e0182086.	2.5	25
68	Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscular Disorders, 2016, 26, 350-353.	0.6	24
69	Neuromuscular junction disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 447-466.	1.8	51
70	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
71	T2 relaxation times are increased in Skeletal muscle of DMD but not BMD patients. Muscle and Nerve, 2016, 53, 38-43.	2.2	42
72	Increased risk for clinical onset of myasthenia gravis during the postpartum period. Neurology, 2016, 87, 2139-2145.	1.1	53

#	Article	IF	Citations
73	Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. European Journal of Neuroscience, 2016, 43, 1623-1635.	2.6	59
74	International consensus guidance for management of myasthenia gravis. Neurology, 2016, 87, 419-425.	1.1	736
75	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. Journal of Neuroimmunology, 2016, 291, 82-88.	2.3	59
76	Myasthenia gravis: subgroup classifications â€“ Authors' reply. Lancet Neurology, The, 2016, 15, 357-358.	10.2	5
77	An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP). Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 790-791.	1.9	10
78	Diagnosis of becker muscular dystrophy: Results of Reâ€analysis of DNA samples. Muscle and Nerve, 2016, 53, 44-48.	2.2	2
79	The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85.	2.6	200
80	Evaluation of skeletal muscle DTI in patients with duchenne muscular dystrophy. NMR in Biomedicine, 2015, 28, 1589-1597.	2.8	93
81	Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations. Molecular Medicine, 2015, 21, 769-781.	4.4	52
82	The expanding field of IgG4â€mediated neurological autoimmune disorders. European Journal of Neurology, 2015, 22, 1151-1161.	3.3	142
83	Geographical Distribution of Myasthenia Gravis in Northern Europe - Results from a Population-Based Study from Two Countries. Neuroepidemiology, 2015, 44, 221-231.	2.3	35
84	The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations. Human Mutation, 2015, 36, 395-402.	2.5	507
85	Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Experimental Neurology, 2015, 270, 29-40.	4.1	27
86	Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. Experimental Neurology, 2015, 270, 41-54.	4.1	43
87	Studying the role of dystrophin-associated proteins in influencing Becker muscular dystrophy disease severity. Neuromuscular Disorders, 2015, 25, 231-237.	0.6	11
88	Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. Journal of Neuroimmunology, 2015, 282, 123-125.	2.3	26
89	Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessingSPP1andLTBP4variants. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1060-1065.	1.9	86
90	An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health and Quality of Life Outcomes, 2015, 13, 115.	2.4	73

#	Article	IF	Citations
91	Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials. BMJ Open, 2015, 5, e007863.	1.9	11
92	Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurology, The, 2015, 14, 1023-1036.	10.2	778
93	Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 96-105.	0.6	39
94	Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Human Molecular Genetics, 2015, 24, 659-669.	2.9	130
95	The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85.	2.6	89
96	Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 92-98.	1.9	29
97	Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes. The Cochrane Library, 2014, 2014, CD010028.	2.8	12
98	Dystrophin levels and clinical severity in Becker muscular dystrophy patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 747-753.	1.9	95
99	Reduced cerebral gray matter and altered white matter in boys with <scp>D</scp>uchenne muscular dystrophy. Annals of Neurology, 2014, 76, 403-411.	5.3	90
100	The Lambert-Eaton Myasthenic Syndrome. , 2014, , 189-204.		0
101	Treatment options for Lambertâ€“Eaton myasthenic syndrome. Expert Opinion on Orphan Drugs, 2014, 2, 159-167.	0.8	0
102	Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 216-221.	0.6	16
103	Temporalis Muscle Hypertrophy and Reduced Skull Eccentricity in Duchenne Muscular Dystrophy. Journal of Child Neurology, 2014, 29, 1344-1348.	1.4	10
104	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	5.8	93
105	Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology, 2014, 83, 1056-1059.	1.1	278
106	Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 409-416.	0.6	134
107	Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibodyâ€binding epitopes in myasthenia gravis. Journal of Internal Medicine, 2014, 275, 12-26.	6.0	45
108	Age-Related Longitudinal Changes in Metabolic Energy Expenditure during Walking in Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2014, 9, e115200.	2.5	14

#	Article	IF	Citations
109	Lambert-Eaton Myasthenic Syndrome. , 2014, , 1089-1099.		0
110	Prolonged Ambulation in Duchenne Patients with a Mutation Amenable to Exon 44 Skipping. Journal of Neuromuscular Diseases, 2014, 1, 91-94.	2.6	24
111	Forty-Five Years of Duchenne Muscular Dystrophy in The Netherlands. Journal of Neuromuscular Diseases, 2014, 1, 99-109.	2.6	22
112	MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20783-20788.	7.1	234
113	Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmunity Reviews, 2013, 12, 918-923.	5.8	143
114	Paraneoplastic Syndromes of the Neuromuscular Junction: Therapeutic Options in Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and Neuromyotonia. Current Treatment Options in Neurology, 2013, 15, 224-239.	1.8	26
115	Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology, 2012, 78, 189-193.	1.1	354
116	Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain, 2012, 135, 1081-1101.	7.6	180
117	Risk for myasthenia gravis maps to a ¹⁵¹Proâ†'Ala change in TNIP1 and to human leukocyte antigenâ€B*08. Annals of Neurology, 2012, 72, 927-935.	5.3	137
118	Exon skipping for DMD. Orphanet Journal of Rare Diseases, 2012, 7, A20.	2.7	1
119	SOX1 antibodies in Lambertâ€"Eaton myasthenic syndrome and screening for small cell lung carcinoma. Annals of the New York Academy of Sciences, 2012, 1275, 70-77.	3.8	20
120	Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 114-122.	3.8	34
121	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	1.6	210
122	Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy. New England Journal of Medicine, 2011, 364, 1513-1522.	27.0	642
123	Neuromuscular synaptic transmission in aged ganglioside-deficient mice. Neurobiology of Aging, 2011, 32, 157-167.	3.1	16
124	IgG Fc N-Glycosylation Changes in Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis. Journal of Proteome Research, 2011, 10, 143-152.	3.7	84
125	Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology, 2011, 18, 19.	3.3	489
126	Lambertâ€"Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurology, The, 2011, 10, 1098-1107.	10.2	372

#	Article	IF	Citations
127	Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain, 2011, 134, 3547-3559.	7.6	125
128	Preâ€•and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle and Nerve, 2010, 42, 283-288.	2.2	53
129	Guidelines for treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology, 2010, 17, 893-902.	3.3	412
130	3,4-diaminopyridine for the treatment of Lambertâ€“Eaton myasthenic syndrome. Expert Review of Clinical Immunology, 2010, 6, 867-874.	3.0	27
131	Clinical aspects of myasthenia explained. Autoimmunity, 2010, 43, 344-352.	2.6	86
132	SOX Antibodies in Small-Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome: Frequency and Relation With Survival. Journal of Clinical Oncology, 2009, 27, 4260-4267.	1.6	178
133	Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation, 2009, 30, 293-299.	2.5	485
134	Prednisone 10Âdays on/10Âdays off in patients with Duchenne muscular dystrophy. Journal of Neurology, 2009, 256, 768-773.	3.6	27
135	Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambertâ€“Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clinical Pharmacology and Therapeutics, 2009, 86, 44-48.	4.7	111
136	The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates. American Journal of Pathology, 2009, 175, 1536-1544.	3.8	37
137	Lambertâ€“Eaton Myasthenic Syndrome. Annals of the New York Academy of Sciences, 2008, 1132, 129-134.	3.8	72
138	Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. Journal of Neuroimmunology, 2008, 195, 151-156.	2.3	122
139	The Lambertâ€“Eaton myasthenic syndrome 1988â€“2008: A clinical picture in 97 patients. Journal of Neuroimmunology, 2008, 201-202, 153-158.	2.3	107
140	Neuromuscular synaptic function in mice lacking major subsets of gangliosides. Neuroscience, 2008, 156, 885-897.	2.3	24
141	FAMILIAL OCCURRENCE OF AUTOIMMUNE MYASTHENIA GRAVIS WITH DIFFERENT ANTIBODY SPECIFICITY. Neurology, 2008, 70, 2011-2013.	1.1	17
142	SOX1 antibodies are markers of paraneoplastic Lambertâ€“Eaton myasthenic syndrome. Neurology, 2008, 70, 924-928.	1.1	220
143	Screening for Small-Cell Lung Cancer: A Follow-Up Study of Patients With Lambert-Eaton Myasthenic Syndrome. Journal of Clinical Oncology, 2008, 26, 4276-4281.	1.6	112
144	A TRANSIENT NEONATAL MYASTHENIC SYNDROME WITH ANTI-MUSK ANTIBODIES. Neurology, 2008, 70, 1215-1216.	1.1	59

#	Article	IF	Citations
145	Local Dystrophin Restoration with Antisense Oligonucleotide PRO051. New England Journal of Medicine, 2007, 357, 2677-2686.	27.0	735
146	Synaptic dysfunction does not contribute to muscle weakness in inclusion-body myositis. Muscle and Nerve, 2007, 35, 266-267.	2.2	1
147	Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opinion on Pharmacotherapy, 2006, 7, 1323-1336.	1.8	45
148	Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology, 2006, 66, 1772-1774.	1.1	114
149	Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 417-418.	1.9	65
150	HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambertâ€“Eaton myasthenic syndrome. Journal of Neuroimmunology, 2005, 159, 230-237.	2.3	80
151	P/Q-type calcium channel antibodies, Lambertâ€“Eaton myasthenic syndrome and survival in small cell lung cancer. Journal of Neuroimmunology, 2005, 164, 161-165.	2.3	65
152	Lambertâ€“Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle and Nerve, 2005, 32, 226-229.	2.2	47
153	The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology, 2004, 63, 397-398.	1.1	55
154	Associated autoimmune diseases in patients with the Lambert-Eaton myasthenic syndrome and their families. Journal of Neurology, 2004, 251, 1255-1259.	3.6	51
155	HLA-B8 in Patients with the Lambert-Eaton Myasthenic Syndrome Reduces Likelihood of Associated Small Cell Lung Carcinoma. Annals of the New York Academy of Sciences, 2003, 998, 200-201.	3.8	13
156	The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. Journal of Neurology, 2003, 250, 698-701.	3.6	92
157	Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. Muscle and Nerve, 2003, 28, 236-238.	2.2	24
158	Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 766-768.	1.9	97
159	Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clinical Neurology and Neurosurgery, 2002, 104, 359-363.	1.4	142
160	Triggering of balance corrections and compensatory strategies in a patient with total leg proprioceptive loss. Experimental Brain Research, 2002, 142, 91-107.	1.5	154
161	HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Human Immunology, 2001, 62, 809-813.	2.4	40
162	Tonic pupils in Lambert-Eaton myasthenic syndrome. Muscle and Nerve, 2001, 24, 444-445.	2.2	22

#	Article	IF	Citations
163	Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology, 2000, 55, 1385-1388.	1.1	187
164	Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 353-357.	1.9	33
165	Antibodies against the calcium channel Î²â€subunit in Lambertâ€Eaton myasthenic syndrome. Neurology, 1998, 50, 475-479.	1.1	43
166	Paraneoplastic anti-Hu serum: studies on human tumor cell lines. Journal of Neuroimmunology, 1997, 79, 202-210.	2.3	41
167	Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.. Journal of Clinical Oncology, 1997, 15, 2866-2872.	1.6	351
168	Age-related susceptibility to experimental autoimmune myasthenia gravis: Immunological and electrophysiological aspects. , 1997, 20, 1091-1101.		18
169	Letters to the editor. Muscle and Nerve, 1993, 16, 109-117.	2.2	2
170	Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis. Journal of Neuroimmunology, 1992, 36, 117-125.	2.3	17
171	In Vivo Effects of Neonatal Administration O Antiidiotype Antibodies on Experimental Autoimmune Myasthenia Gravis. Autoimmunity, 1991, 10, 173-179.	2.6	6
172	Paratope- and framework-related cross-reactive idiotopes on anti-acetylcholine receptor antibodies. Journal of Immunology, 1991, 146, 941-8.	0.8	13
173	Single-fiber electromyography in experimental autoimmune myasthenia gravis. Muscle and Nerve, 1990, 13, 485-492.	2.2	31
174	â€˜Spontaneousâ€™ Myasthenia Gravis in a rat after syngeneic bone marrow transplantation. Journal of Autoimmunity, 1989, 2, 909-910.	6.5	1
175	Experimental autoimmune Myasthenia Gravis analysed by stimulated single fiber electromyography. Journal of Autoimmunity, 1989, 2, 919-920.	6.5	0
176	Monoclonal and polyclonal anti-acetylcholine receptor antibodies share crossreactive idiotopes. Journal of Autoimmunity, 1989, 2, 906.	6.5	0
177	3,4-Diaminopyridine for myasthenia gravis. The Cochrane Library, 0, , .	2.8	0